Clinical Research Directory

Inclusion Criteria: 1. age ≥ 65 years; 2. endoscopically proven acute nonvariceal GIB source; 3. 48 hours after the endoscopic diagnosis and/or treatment; 4. hemodynamically stable; 5. the discharge of the patient is planned; 6. hemoglobin level \<10 g/dl on the day of randomisation; 7. 24 hours after the last transfusion and no need for further transfusion; 8. signed informed consent. Exclusion Criteria: 1. known hypersensitivity to iron products (mild side effects excluded); 2. previous diagnosis of iron overload \[e.g., transferrin receptor saturation (TSAT) \>50%, ferritin\> 160 for women ng/ml, ferritin \>270 ng/ml for men) or disorders of iron utilisation; 3. pregnancy or breast feeding; 4. diagnosis of iron malabsorption (at discretion of the attending clinician; e.g., severe inflammatory bowel disease, active celiac disease); 5. chronic end stage diseases (chronic heart failure-New York Heart Association Classification class 4, chronic kidney disease (eGFR \<30 mL/min/1.73 m2) with or without dialysis, liver cirrhosis with Child Pugh C score, chronic kidney disease with dialysis, chronic obstructive pulmonary disease stage 4, chronic inflammatory disease, malignancies, AIDS); 6. active malignancies; 7. liver cirrhosis with known varices at high risk of bleeding - endoscopic features of high risk of variceal bleeding or liver stiffness measured by transient elastography \>20 kiloPascal and platelet count \<150 × 10\^9 cells/L; 8. gastrointestinal tract malignancies with high risk of gastrointestinal bleeding; 9. high risk of poor compliance or no fixed abode; 10. myelo- or lymphoproliferative diseases; 11. anemia not attributable to iron deficiency (sideroblastic anaemia, aplastic anaemia, haemolytic anaemia, thalassaemia, B12 vitamin or folic acid deficiency or combination of these with IDA); 12. primary coagulation disorders (e.g. Glanzmann thrombasthenia, Von Willebrand disease, Haemophylia A, Haemophylia B); 13. the patient will be transferred to another institute after discharge (e.g. hospital, senior care center); 14. Eastern Cooperative Oncology Group (ECOG) Performance Status \>2.